Form 4 for ACRV Acrivon Therapeutics, Inc.
Accepted 2024-11-18 00:00:00 ET · period of report 2024-11-14 · accession 0000905148-24-003223 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-11-18 | 2024-11-14 | ACRV | Blume-Jensen Peter | Pres, CEO, Dir | F - Tax | $7.92 | -59.8K | 2.36M | -2% | -$473.3K | |
| I | 2024-11-18 | 2024-11-14 | ACRV | Blume-Jensen Peter | Pres, CEO, Dir | F - Tax | $7.92 | -490 | 316.8K | -0.2% | -$3,881 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-14 | F | D | 59,766 | $7.92 | 2,362,747 | D See Footnote | — | — | (F2) These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. (F3) These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
| 2 | Common | Common Stock | 2024-11-14 | F | D | 490 | $7.92 | 316,756 | I | — | — |